Adjuvant Chemotherapy Yields Improved Overall Survival in PDAC Population Aged 80 Years or Older
January 17, 2022

Patients undergoing pancreaticoduodenectomy for pancreatic ductal adenocarcinoma experienced a better overall survival when treated with adjuvant chemotherapy.

Blood-Based Biomarker Panel Plus Personalized Risk Model Improved Risk Assessment for Lung Cancer Screenings
January 17, 2022

Investigators reported that combining a blood-based biomarker panel with PLCOm2012 resulted in a significant improvement in risk assessment for lung cancer screenings.

Trastuzumab Deruxtecan Granted Priority Review From FDA for HER2-Positive Metastatic Breast Cancer
January 17, 2022

Fam-trastuzumab deruxtecan-nxki, which was granted a priority review designation, appears to have potential for patients with HER2-positive metastatic breast cancer.

Waiting Time for Ovarian Cancer Treatment Found to be Longer Than Almost all Other Malignancies
January 17, 2022

Women diagnosed with ovarian cancer were reported to have longer waiting times for treatment vs other cancer types with the exception of kidney cancer.

Future Treatment Landscape of Metastatic Urothelial Carcinoma
January 17, 2022

Closing their discussion on metastatic urothelial carcinoma, panelists reflect on novel agents and the future treatment paradigm.

Selecting Second-Line Therapy for Metastatic Urothelial Carcinoma
January 17, 2022

Expert perspectives on the selection of second-line therapy after a patient has progressed on maintenance avelumab.

The TITAN Study: Secondary End Points
January 17, 2022

Neeraj Agarwal, MD, and Simon Chowdhury, MD, comment on the secondary end points from the final analysis of the TITAN trial.

Lindsey Roeker, MD, Discusses Potential for BTK Inhibition Plus Umbralisib/Ublituximab in CLL
January 17, 2022

Lindsey Roeker, MD, spoke about identifying the correct population of patients with chronic lymphocytic leukemia who will benefit from umbralisib and ublituximab plus ibrutinib.

Community-Based Medical Oncology Depression Screening Program Delivers More Referrals for Behavioral Care in Breast Cancer
January 16, 2022

Patients with breast cancer who were treated at a community-based oncology practice that used routine depression screening were more likely to a receive referral for behavioral care vs those in an education-only cohort.

Fonseca on Findings for First- Vs Second-Line Daratumumab for Transplant-Ineligible Myeloma
January 16, 2022

CancerNetwork® spoke with Rafael Fonseca, MD, about findings from a simulation using real-world data sets to compare the utility of daratumumab-containing regimens as either frontline or second-line therapy.